Effect of cervical cancer screening programs on preterm birth: A decision and cost-effectiveness analysis

Esmé I. Kamphuis, Steffie K. Naber, Noor A. Danhof, J. Dik F. Habbema, Christianne J.M. De Groot, Ben Mol

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: To assess the effect of age at initiation and interval of cervical cancer screening in women of reproductive age on the risk of future preterm birth and subsequent adverse neonatal outcome relative to maternal life-years gained and cost of both screening and preterm birth. METHODS: In this decision and cost-effectiveness analysis, we compared eight cytology-based screening programs varying in age of onset (21, 24, 25, 27, or 30 years) and screening interval (3 or 5 years) in a fictive cohort of 100,000 women. We used the microsimulation screening analysis model to estimate number of cervical intraepithelial neoplasia diagnoses, large loop excisions of the transformation zone (LLETZs), life-years gained, cervical cancer cases, deaths, and costs of screening and treatment. We used the number of LLETZs to calculate additional preterm births, subsequent neonatal morbidity, mortality, and associated costs. RESULTS: The number of LLETZs per 100,000 women varied from 9,612 for the most intensive screening (every 3 years from age 21 years) to 4,646 for the least intensive screening (every 5 years from age 30 years). Compared with the least intensive program, the most intensive program increased maternal life-years gained by 9% (10,728 compared with 9,839), decreased cervical cancer cases by 67% (52 compared with 158), and cervical cancer deaths by 75% (four compared with 16) at the expense of 250% (158 compared with 45) more preterm births and 320% (four compared with one) more neonatal deaths while increasing total costs by $55 million ($77 compared with $23 million). The number of maternal life-years gained per additional preterm birth varied from 68 to 258 with subsequent total costs per maternal life-years gained of $7,212 and $2,329. CONCLUSION: Cervical cancer screening every 3 years and subsequent treatment in women aged younger than 30 years yield limited life-years but may have substantial perinatal adverse effects. Consequently, women who plan to have children may benefit from a more cautious screening approach, taking into account their risk for both cancer and preterm birth.

LanguageEnglish
Pages1207-1217
Number of pages11
JournalObstetrics and Gynecology
Volume130
Issue number6
DOIs
Publication statusPublished - 1 Jan 2017

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Kamphuis, E. I., Naber, S. K., Danhof, N. A., Habbema, J. D. F., De Groot, C. J. M., & Mol, B. (2017). Effect of cervical cancer screening programs on preterm birth: A decision and cost-effectiveness analysis. Obstetrics and Gynecology, 130(6), 1207-1217. https://doi.org/10.1097/AOG.0000000000002366
Kamphuis, Esmé I. ; Naber, Steffie K. ; Danhof, Noor A. ; Habbema, J. Dik F. ; De Groot, Christianne J.M. ; Mol, Ben. / Effect of cervical cancer screening programs on preterm birth : A decision and cost-effectiveness analysis. In: Obstetrics and Gynecology. 2017 ; Vol. 130, No. 6. pp. 1207-1217.
@article{36092189db7e4a30a639b4c3c0e38b2b,
title = "Effect of cervical cancer screening programs on preterm birth: A decision and cost-effectiveness analysis",
abstract = "OBJECTIVE: To assess the effect of age at initiation and interval of cervical cancer screening in women of reproductive age on the risk of future preterm birth and subsequent adverse neonatal outcome relative to maternal life-years gained and cost of both screening and preterm birth. METHODS: In this decision and cost-effectiveness analysis, we compared eight cytology-based screening programs varying in age of onset (21, 24, 25, 27, or 30 years) and screening interval (3 or 5 years) in a fictive cohort of 100,000 women. We used the microsimulation screening analysis model to estimate number of cervical intraepithelial neoplasia diagnoses, large loop excisions of the transformation zone (LLETZs), life-years gained, cervical cancer cases, deaths, and costs of screening and treatment. We used the number of LLETZs to calculate additional preterm births, subsequent neonatal morbidity, mortality, and associated costs. RESULTS: The number of LLETZs per 100,000 women varied from 9,612 for the most intensive screening (every 3 years from age 21 years) to 4,646 for the least intensive screening (every 5 years from age 30 years). Compared with the least intensive program, the most intensive program increased maternal life-years gained by 9{\%} (10,728 compared with 9,839), decreased cervical cancer cases by 67{\%} (52 compared with 158), and cervical cancer deaths by 75{\%} (four compared with 16) at the expense of 250{\%} (158 compared with 45) more preterm births and 320{\%} (four compared with one) more neonatal deaths while increasing total costs by $55 million ($77 compared with $23 million). The number of maternal life-years gained per additional preterm birth varied from 68 to 258 with subsequent total costs per maternal life-years gained of $7,212 and $2,329. CONCLUSION: Cervical cancer screening every 3 years and subsequent treatment in women aged younger than 30 years yield limited life-years but may have substantial perinatal adverse effects. Consequently, women who plan to have children may benefit from a more cautious screening approach, taking into account their risk for both cancer and preterm birth.",
author = "Kamphuis, {Esm{\'e} I.} and Naber, {Steffie K.} and Danhof, {Noor A.} and Habbema, {J. Dik F.} and {De Groot}, {Christianne J.M.} and Ben Mol",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/AOG.0000000000002366",
language = "English",
volume = "130",
pages = "1207--1217",
journal = "Obstetrics and gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Kamphuis, EI, Naber, SK, Danhof, NA, Habbema, JDF, De Groot, CJM & Mol, B 2017, 'Effect of cervical cancer screening programs on preterm birth: A decision and cost-effectiveness analysis', Obstetrics and Gynecology, vol. 130, no. 6, pp. 1207-1217. https://doi.org/10.1097/AOG.0000000000002366

Effect of cervical cancer screening programs on preterm birth : A decision and cost-effectiveness analysis. / Kamphuis, Esmé I.; Naber, Steffie K.; Danhof, Noor A.; Habbema, J. Dik F.; De Groot, Christianne J.M.; Mol, Ben.

In: Obstetrics and Gynecology, Vol. 130, No. 6, 01.01.2017, p. 1207-1217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of cervical cancer screening programs on preterm birth

T2 - Obstetrics and gynecology

AU - Kamphuis, Esmé I.

AU - Naber, Steffie K.

AU - Danhof, Noor A.

AU - Habbema, J. Dik F.

AU - De Groot, Christianne J.M.

AU - Mol, Ben

PY - 2017/1/1

Y1 - 2017/1/1

N2 - OBJECTIVE: To assess the effect of age at initiation and interval of cervical cancer screening in women of reproductive age on the risk of future preterm birth and subsequent adverse neonatal outcome relative to maternal life-years gained and cost of both screening and preterm birth. METHODS: In this decision and cost-effectiveness analysis, we compared eight cytology-based screening programs varying in age of onset (21, 24, 25, 27, or 30 years) and screening interval (3 or 5 years) in a fictive cohort of 100,000 women. We used the microsimulation screening analysis model to estimate number of cervical intraepithelial neoplasia diagnoses, large loop excisions of the transformation zone (LLETZs), life-years gained, cervical cancer cases, deaths, and costs of screening and treatment. We used the number of LLETZs to calculate additional preterm births, subsequent neonatal morbidity, mortality, and associated costs. RESULTS: The number of LLETZs per 100,000 women varied from 9,612 for the most intensive screening (every 3 years from age 21 years) to 4,646 for the least intensive screening (every 5 years from age 30 years). Compared with the least intensive program, the most intensive program increased maternal life-years gained by 9% (10,728 compared with 9,839), decreased cervical cancer cases by 67% (52 compared with 158), and cervical cancer deaths by 75% (four compared with 16) at the expense of 250% (158 compared with 45) more preterm births and 320% (four compared with one) more neonatal deaths while increasing total costs by $55 million ($77 compared with $23 million). The number of maternal life-years gained per additional preterm birth varied from 68 to 258 with subsequent total costs per maternal life-years gained of $7,212 and $2,329. CONCLUSION: Cervical cancer screening every 3 years and subsequent treatment in women aged younger than 30 years yield limited life-years but may have substantial perinatal adverse effects. Consequently, women who plan to have children may benefit from a more cautious screening approach, taking into account their risk for both cancer and preterm birth.

AB - OBJECTIVE: To assess the effect of age at initiation and interval of cervical cancer screening in women of reproductive age on the risk of future preterm birth and subsequent adverse neonatal outcome relative to maternal life-years gained and cost of both screening and preterm birth. METHODS: In this decision and cost-effectiveness analysis, we compared eight cytology-based screening programs varying in age of onset (21, 24, 25, 27, or 30 years) and screening interval (3 or 5 years) in a fictive cohort of 100,000 women. We used the microsimulation screening analysis model to estimate number of cervical intraepithelial neoplasia diagnoses, large loop excisions of the transformation zone (LLETZs), life-years gained, cervical cancer cases, deaths, and costs of screening and treatment. We used the number of LLETZs to calculate additional preterm births, subsequent neonatal morbidity, mortality, and associated costs. RESULTS: The number of LLETZs per 100,000 women varied from 9,612 for the most intensive screening (every 3 years from age 21 years) to 4,646 for the least intensive screening (every 5 years from age 30 years). Compared with the least intensive program, the most intensive program increased maternal life-years gained by 9% (10,728 compared with 9,839), decreased cervical cancer cases by 67% (52 compared with 158), and cervical cancer deaths by 75% (four compared with 16) at the expense of 250% (158 compared with 45) more preterm births and 320% (four compared with one) more neonatal deaths while increasing total costs by $55 million ($77 compared with $23 million). The number of maternal life-years gained per additional preterm birth varied from 68 to 258 with subsequent total costs per maternal life-years gained of $7,212 and $2,329. CONCLUSION: Cervical cancer screening every 3 years and subsequent treatment in women aged younger than 30 years yield limited life-years but may have substantial perinatal adverse effects. Consequently, women who plan to have children may benefit from a more cautious screening approach, taking into account their risk for both cancer and preterm birth.

UR - http://www.scopus.com/inward/record.url?scp=85039841337&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000002366

DO - 10.1097/AOG.0000000000002366

M3 - Article

VL - 130

SP - 1207

EP - 1217

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

SN - 0029-7844

IS - 6

ER -